{"disease":{"id":"multiple-sclerosis-relapsing-remitting","name":"multiple sclerosis relapsing remitting"},"drugs":{"marketed":[{"drug_id":"mitoxantrone","indication_name":"Multiple Sclerosis - Worsening Relapsing-Remitting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05605782","title":"A Post-Authorization, Long-term Study of Ozanimod Real-world Safety","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9000,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06854341","title":"A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data","phase":"","overall_status":"COMPLETED","enrollment_count":5448,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06705608","title":"Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study","phase":"","overall_status":"COMPLETED","enrollment_count":4000,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT04756687","title":"Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera","phase":"","overall_status":"COMPLETED","enrollment_count":1507,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT03085810","title":"Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1225,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04121221","title":"A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1016,"lead_sponsor_name":"Mapi Pharma Ltd.","has_results":false},{"nct_id":"NCT05204459","title":"MS-ResearchBiomarkerS","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT03500328","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":900,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT03535298","title":"Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT02861014","title":"A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":681,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT03347370","title":"A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":626,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT02637856","title":"A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":608,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT03689972","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":585,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT04580381","title":"Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT02247310","title":"BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon","phase":"","overall_status":"COMPLETED","enrollment_count":498,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06127095","title":"A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments","phase":"","overall_status":"COMPLETED","enrollment_count":474,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT04655222","title":"Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program","phase":"","overall_status":"COMPLETED","enrollment_count":470,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT05335031","title":"A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)","phase":"","overall_status":"COMPLETED","enrollment_count":450,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02744222","title":"Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":399,"lead_sponsor_name":"Biocad","has_results":false},{"nct_id":"NCT05758831","title":"RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":386,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT06345157","title":"ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":379,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04221191","title":"Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP","phase":"","overall_status":"COMPLETED","enrollment_count":353,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT06526000","title":"Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies","phase":"","overall_status":"COMPLETED","enrollment_count":326,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT03283397","title":"A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":301,"lead_sponsor_name":"Bosnalijek D.D","has_results":false},{"nct_id":"NCT07222618","title":"\"Selfie\" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT05019248","title":"Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine","phase":"","overall_status":"UNKNOWN","enrollment_count":260,"lead_sponsor_name":"Heinrich-Heine University, Duesseldorf","has_results":false},{"nct_id":"NCT02598167","title":"Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition","phase":"","overall_status":"COMPLETED","enrollment_count":223,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02579681","title":"Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":221,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT00676715","title":"A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT03239860","title":"Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":220,"lead_sponsor_name":"GeNeuro SA","has_results":false},{"nct_id":"NCT02525874","title":"Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":218,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT04450030","title":"Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis","phase":"","overall_status":"UNKNOWN","enrollment_count":204,"lead_sponsor_name":"University Hospital Muenster","has_results":false},{"nct_id":"NCT02064816","title":"A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Merck KGaA, Darmstadt, Germany","has_results":true},{"nct_id":"NCT03205280","title":"Clinical Decision Support System (CADIMS) for MS Diagnostic","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT03979456","title":"RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT06325358","title":"the EXPOSITION Study","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"University of Pavia","has_results":false},{"nct_id":"NCT06408259","title":"Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":194,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT07235644","title":"Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT05029206","title":"Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden","phase":"","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT05366036","title":"A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":172,"lead_sponsor_name":"Eisai Korea Inc.","has_results":false},{"nct_id":"NCT04966338","title":"Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":170,"lead_sponsor_name":"Cinnagen","has_results":false},{"nct_id":"NCT05007483","title":"Efficacy of Diet on Quality of Life in Multiple Sclerosis","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":162,"lead_sponsor_name":"Terry L. Wahls","has_results":false},{"nct_id":"NCT03610139","title":"Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":162,"lead_sponsor_name":"American University of Beirut Medical Center","has_results":false},{"nct_id":"NCT02633033","title":"Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse","phase":"","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Mallinckrodt","has_results":false},{"nct_id":"NCT04233970","title":"Development and Evaluation of a Web-based Programme on Relapse Management for People With Multiple Sclerosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT06897657","title":"A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients","phase":"","overall_status":"COMPLETED","enrollment_count":155,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03958877","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":152,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT05417269","title":"IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Imcyse SA","has_results":false},{"nct_id":"NCT02652091","title":"Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction","phase":"","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Bayer","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}